8-K: Akebia Therapeutics Announces First Quarter 2024 Financial Results and Vafseo Launch Update

Akebia Therapeutics reported its first quarter 2024 financial results, highlighted by the FDA approval of Vafseo and ongoing launch preparations.

Summary

• Akebia Therapeutics announced its financial results for the first quarter of 2024, with total revenues of $32.6 million, a decrease from $40.0 million in the same period of 2023.
• Net product revenues were $31.0 million, down from $34.7 million in the first quarter of 2023, while license, collaboration, and other revenues decreased to $1.6 million from $5.3 million.
• The company's net loss for the quarter was $18.0 million, an improvement from a net loss of $26.9 million in the first quarter of 2023.
• Cost of goods sold decreased to $11.6 million from $20.2 million, and research and development expenses also decreased to $9.7 million from $19.7 million.
• Selling, general, and administrative expenses were $25.4 million, slightly up from $25.1 million in the prior year.
• Akebia's cash and cash equivalents stood at approximately $42.0 million as of March 31, 2024.
• The company expects its current cash resources and cash from operations to be sufficient to fund operations for at least the next two years, including the Vafseo launch.
• Vafseo (vadadustat) was approved by the FDA on March 27, 2024, and the launch is planned for January 2025.
• Akebia is also working on a Transitional Drug Add-on Payment Adjustment (TDAPA) application for Vafseo, expected to be submitted in June and potentially approved in January 2025.
• Auryxia net product revenues were $31.0 million for the first quarter of 2024, and the company expects revenue growth for Auryxia in 2024 compared to 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the FDA approval of Vafseo and the expected launch are positive, the decrease in revenue and the risks associated with the launch and the drug itself temper the overall sentiment. The improved net loss and sufficient cash runway are also positive factors.

Positives

• Vafseo's FDA approval is a significant milestone for Akebia, opening a new revenue stream.
• The company expects Auryxia revenue growth in 2024, indicating continued performance of existing products.
• The simplification of repayment terms with Vifor International Ltd. is a positive development.
• The reduction in net loss from $26.9 million to $18.0 million year-over-year shows improved financial performance.
• Akebia has sufficient cash to fund operations for at least the next two years, providing financial stability.

Negatives

• Total revenues decreased to $32.6 million in Q1 2024 from $40.0 million in Q1 2023.
• Net product revenues decreased to $31.0 million in Q1 2024 from $34.7 million in Q1 2023.
• License, collaboration, and other revenues decreased to $1.6 million in Q1 2024 from $5.3 million in Q1 2023.

Risks

• The commercial launch of Vafseo in January 2025 is subject to execution risks.
• The TDAPA application for Vafseo may not be accepted or approved as expected.
• There are risks associated with the market acceptance and reimbursement of Vafseo and Auryxia.
• The company faces competition from other treatments for anemia due to chronic kidney disease.
• There are risks associated with manufacturing, supply chain, and quality control.
• The company is subject to regulatory risks, including decisions made by health authorities like the FDA.
• Vafseo carries a boxed warning regarding increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access.

Future Outlook

Akebia expects its existing cash resources and cash from operations will be sufficient to fund its current operating plan, including a U.S. Vafseo launch, for at least the next two years. The company anticipates Auryxia net product revenue growth in 2024 versus 2023 and plans to engage with the FDA on label expansion opportunities for Vafseo by the end of this year.

Management Comments

• John P. Butler, Chief Executive Officer of Akebia, stated that the FDA approval of Vafseo represents a transformational milestone for Akebia.
• Mr. Butler also mentioned that the company is progressing plans for generating clinical data to identify additional areas of potential benefit to patients.
• Mr. Butler added that with continued revenue contributions from Auryxia, revenue from Vafseo beginning in 2025, and the current cash balance, the company believes it has sufficient cash to support operations for at least the next two years while investing in the Vafseo launch.

Industry Context

The approval of Vafseo and its planned launch positions Akebia in the competitive market for treatments for anemia due to chronic kidney disease. The company's focus on both Vafseo and Auryxia, along with its efforts to secure TDAPA designation, reflects a strategy to maximize its market presence and revenue potential in the renal space. The submission of a marketing authorization application by Averoa for Ferric Citrate Coordination Complex in Europe also indicates a broader global strategy.

Comparison to Industry Standards

• Akebia's Q1 2024 revenue of $32.6 million is lower than the $40.0 million reported in Q1 2023, indicating a potential challenge in maintaining revenue growth compared to previous periods.
• The company's net loss of $18.0 million in Q1 2024 is an improvement compared to the $26.9 million loss in Q1 2023, suggesting progress in cost management and operational efficiency.
• The successful FDA approval of Vafseo is a significant achievement, placing Akebia in a position to compete with other companies offering treatments for anemia in dialysis patients, such as those using erythropoiesis-stimulating agents (ESAs).
• The planned launch of Vafseo in January 2025 will be a key event to watch, as its success will depend on market acceptance, reimbursement, and the company's ability to effectively commercialize the product.
• Akebia's cash position of approximately $42.0 million as of March 31, 2024, is a critical factor in its ability to fund operations and the Vafseo launch, and the company's statement that it has sufficient cash for at least two years is a positive sign for investors.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of the Vafseo launch.
• Employees will be involved in the launch of Vafseo and the continued commercialization of Auryxia.
• Patients with chronic kidney disease will benefit from the availability of Vafseo as a new treatment option.
• Dialysis providers will be key partners in the commercialization of both Vafseo and Auryxia.
• Creditors will be interested in the company's financial stability and ability to repay its debts.

Next Steps

• Akebia will submit its TDAPA application for Vafseo in June 2024.
• Akebia will continue launch activities for Vafseo, with commercial availability expected in January 2025.
• Akebia will engage with the FDA on label expansion opportunities for Vafseo by the end of this year.
• Akebia will continue to contract with dialysis organizations to ensure broad access to Auryxia.

Key Dates

Keywords

Vafseo, vadadustat, Auryxia, ferric citrate, anemia, chronic kidney disease, CKD, FDA approval, TDAPA, dialysis, biopharmaceutical, revenue, financial results